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Abstract
Background: Systematic processing noise, which includes batch effects, is very common in microarray experiments
but is often ignored despite its potential to confound or compromise experimental results. Compromised results
are most likely when re-analysing or integrating datasets from public repositories due to the different conditions
under which each dataset is generated. To better understand the relative noise-contributions of various factors in
experimental-design, we assessed several Illumina and Affymetrix datasets for technical variation between replicate
hybridisations of Universal Human Reference (UHRR) and individual or pooled breast-tumour RNA.
Results: A varying degree of systematic noise was observed in each of the datasets, however in all cases the
relative amount of variation between standard control RNA replicates was found to be greatest at earlier points in
the sample-preparation workflow. For example, 40.6% of the total variation in reported expressions were attributed
to replicate extractions, compared to 13.9% due to amplification/labelling and 10.8% between replicate
hybridisations. Deliberate probe-wise batch-correction methods were effective in reducing the magnitude of this
variation, although the level of improvement was dependent on the sources of noise included in the model.
Systematic noise introduced at the chip, run, and experiment levels of a combined Illumina dataset were found to
be highly dependant upon the experimental design. Both UHRR and pools of RNA, which were derived from the
samples of interest, modelled technical variation well although the pools were significantly better correlated (4%
average improvement) and better emulated the effects of systematic noise, over all probes, than the UHRRs. The
effect of this noise was not uniform over all probes, with low GC-content probes found to be more vulnerable to
batch variation than probes with a higher GC-content.
Conclusions: The magnitude of systematic processing noise in a microarray experiment is variable across probes
and experiments, however it is generally the case that procedures earlier in the sample-preparation workflow are
liable to introduce the most noise. Careful experimental design is important to protect against noise, detailed
meta-data should always be provided, and diagnostic procedures should be routinely performed prior to
downstream analyses for the detection of bias in microarray studies.
Background
Increased adoption of high-throughput, whole-genome
gene expression analysis technologies has led to an
increased focus on the reliability of the experimental
measurements they produce. Several recent articles have
provided substantial evidence that systematic noise
introduced as a result of batch-processing have a detri-
mental effect on data derived from microarrays [1-5].
Complete confounding of batches of array scans (even
in the same laboratory, but at different times) with the
variable under investigation can completely undermine
reported results. For example, re-analysis of a study by
Spielman et al. [6] revealed that samples from each of
their studied populations were processed separately
(between 1-3 years apart) and that after application of a
standard batch-correction method [7] none of the genes
initially reported remained significantly differentially
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reliability and consistency of array measurements and
estimate potential sources of confounding systematic
noise in an e ort to reduce these vulnerabilities [9,10].
The microarray quality control (MAQC) project was
established to explore inter-platform and inter-labora-
tory consistency of microarray-derived gene expression
datasets using two reference RNA samples [11], as well
as consistency of differential expression estimates
[12,13]. These studies reported generally good consensus
between replicate samples across technologies and
laboratories, however the latter found the greatest level
of consistency in results-lists between platforms was
achieved when probes were ranked by decreasing fold-
change with a generous p-value cutoff [13]. Despite this
finding, it is still the case that most published studies
determine whether or not genes are differentially
expressed based on the significance of statistical tests.
Our own previous studies have reported compelling evi-
dence for the existence of confounding batch effects in
Affymetrix and Illumina experiments performed in the
same laboratory using a single platform [14,15]. It has
also been shown that batch effects can be mitigated
using per-probe batch-correction methods such as
mean-centring [14], distance-weighted discrimination
(DWD) [16], or empirical-Bayes corrections [17].
Awareness of and protection from batch effects is of
particular importance in meta- or re-analyses of existing
data, collated from multiple sources, where the intention
is to exploit increased statistical power to detect subtle
differences in expression between well-defined
phenotypes. Direct comparison and integration of gene
expression data through re-analyses is a highly attractive
option due to data repositories such as the NCBI Gene
Expression Omnibus (GEO) [18] and Array Express
hosted by the European Bioinformatics Institute [19].
Unfortunately appraising the quality of publicly available
data is not a trivial task and, even when the submission
guidelines are followed completely, it can be difficult to
identify technical issues that may lead to systematic
noise in subsequent analysis that potentially compromise
results. It is important therefore to have an appreciation
of the relative sources of systematic error throughout
the experiment to prioritise which elements of meta-
data should accompany published datasets and, subse-
quently, how to evaluate the experiment design to
enable reliable re-analysis or integration of published
data.
Given previously reported variation in various array
technologies [14,15,20-23], we wished to quantify the
relative noise introduced at various stages in the
experimental process prior to array scanning; including
the choice of experimental protocol, array-version, and
study design. In addition, we assess different types of
control sample in terms of their ability to model batch
effects and also consider correlations to specific prop-
erties of array probes. In this study, we present an ana-
lysis of in-house Affymetrix (Figure 1A) and Illumina
(Figure 1B) datasets in addition to those generated as
part of the MAQC project [11] (Figure 1C) in order to
assess the relative bias introduced in microarray
results.
Figure 1 Experiment designs.S c h e m a t i cc o m p a r i s o no ft h es a m p l ep r e -processing used in the generation of A: the previously published
MCF7 and MCF10A Affymetrix GeneChips, B: our Illumina Ref-8/HT-12 data, and C: the MAQC Illumina/Affymetrix data.
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Relative sources of systematic noise associated with
various stages in the Affymetrix experiment workflow
In order to establish the relative impact of different
sources of systematic noise we compared the expression
profiles and numbers of consistently differentially
expressed genes when compensating for variation intro-
duced at a single or at multiple steps in the Affymetrix
GeneChip sample-processing workflow. The dataset,
previously reported in [14], consisted of MCF7 and
MCF10A samples for which technical replicates were
available at several stages of sample preparation (Figure
1A). We previously observed that the variability intro-
duced by different generations of array platform or
amplification protocol was larger than that attributed to
the choice of scanner used for image-capture. This was
also reflected in the number of commonly differentially
expressed genes across datasets (Eg. MCF7-amplified/
MCF10A-unamplified vs. MCF7-unamplified/MCF10A-
amplified), which were fewer between platforms/
protocols than between scanners. In the current study,
we found that when batch correction (using ComBat
[17]) is performed to enable integration of these data-
sets, compensating for the bias introduced by amplifica-
tion and labelling resulted in much greater consistency
in gene-lists (46% and 66% average improvement) than
correcting for the scanner (11% improvement), see Fig-
ure 2. Correction for significant sources of systematic
error is required to improve the likelihood of consis-
tently identifying differentially expressed genes from dif-
ferent datasets, but these approaches do not completely
remove all sources of technical error.
Variance analysis of this dataset provided a more
detailed breakdown of the estimated biological and
technical error introduced at the various stages of sam-
ple-preparation (Figure 3A). The majority of the pro-
besets show far greater inter-sample variability than
between the two cell-lines. Cell-line to cell-line (MCF7
vs. MCF10A) variability, mean-averaged over all probe-
sets, contributed 9.6% to the total standard deviation;
Figure 2 Relative comparison of different batch effects in Affymetrix GeneChip data. LEFT, Comparison of the numbers of differentially
expressed genes in common between MCF7 and MCF10A triplicate samples depending upon what variables were included in the model used
for the ComBat correction (’amp’ = amplification, ‘lab’ = labelling, and ‘scn’ = scanner). Red points are mean counts, error bars are standard
deviations, and significance of increased counts compared to no ComBat correction are indicated (’**’ for p < 0:05 and ‘***’ for p < 0:01, based
on two-tailed t-tests). RIGHT, Pairwise Pearson correlation heatmaps of MCF7 and MCF10A samples compensating for 1, 2, or 3 sources of batch
effect using ComBat. Green and blue colour-bars denote MCF7 and MCF10A samples, respectively. The lightest colours denote un-amplified
samples, slightly darker are amplified samples, and the darkest colours are the scanner/labelling comparison. A, all data treated as a single group
without batch-correction; B, batch-correction for amplification; C, batch-correction for amplification and an alternative labelling method; D, batch
correction for amplification, labelling and different scanners used.
Kitchen et al. BMC Genomics 2011, 12:589
http://www.biomedcentral.com/1471-2164/12/589
Page 3 of 14compared to 40.6% due to inter-sample variability,
13.9% due to amplification/labelling, 9.9% & 10.8% for
inter array and inter-scanner, and 15.2% at the within-
scanner/residual level. The arrays were preprocessed
using the popular RMA algorithm for background cor-
rection followed by quantile normalisation (see meth-
ods), however not performing any background
correction resulted in a similar relative variance pro le
but noticeably reduced absolute variances (Additional
File 1). Either with or without background correction,
this error pro le is not at all dissimilar to error esti-
mates obtained from the various stages of sample pre-
paration prior to a qPCR experiment in which the
sampling step is usually by far the most variable while
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Figure 3 Comparison of variance components in Affymetrix and Illumina data. Comparison of MAQC and Paterson Affymetrix variance
components. A: Probe-wise SD-estimates corresponding to several levels of technical variance (see figure key) in detection-filtered and quantile
normalised MCF7/MCF10 expressions from the Paterson Affymetrix dataset. B: Probe-wise estimates of standard deviations (SD) corresponding to
the inter-experiment (light blue), inter-run (dark blue), and inter-chip (green) technical variance in our UHRR Illumina data. The effect on these
standard deviations following detection-filtering (DF), quantile-normalisation (QN), ComBat batch-correction by experiment (CB(expt)), and
ComBat batch-correction by run (CB(run)) are shown. C: Probe-wise SD-estimates corresponding to inter-laboratory (pale blue), inter-chip (green),
and inter-array (dark green) technical variances in detection-filtered and quantile normalised UHRR/UBRR expressions from the MAQC Illumina
dataset. D: Probe-wise SD-estimates corresponding to inter-laboratory (pale blue) and inter-chip (green) technical variances in detection-filtered
and quantile normalised UHRR/UBRR expressions from the MAQC Affymetrix dataset.
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generally low, but can sometimes be larger than sam-
pling error [24].
Technical processing noise across Illumina Beadarray
chip, runs, and experiments
Variance estimates were calculated for each of 15,757
probes at the inter-experiment, inter-run, and inter-chip
level using a nested analysis of variance described in
methods (Figure 1B, Figure 3B, and Additional File 2).
The inter-experiment variance was the parameter with
the greatest source of measurement noise, accounting
for an average 61.7% of the total variation in reported
gene expression. This is likely to be due to the use of a
fresh round of amplification and labelling performed on
the UHRR samples between experiments. Despite an
overall reduction in the technical variation between
probes, the fraction of the total variance contributed by
each level (inter-chip, -run, and -experiment) was unaf-
fected by standard, array-wise, quantile normalisation.
Specific, probe-wise, batch correction greatly reduces
the technical variation due to experiment and run (Fig-
ure 3B). The slight effect due to the within-batch var-
iance moderation can be measured in the reduction in
inter-chip SD after either run of ComBat.T h eh i g h
inter-chip variation, compared to inter-run variation,
appears to be driven by the new samples run on the
HT-12 chips as this was not observed in the standalone
analyses of the Ref-8 data alone. As with the Affymetrix
data we explored the effect of background correction on
these variances (Additional File 1); the practice of cor-
recting for background signal in Illumina arrays is not
as common as when processing Affymetrix data so we
compared variances between preprocessing using quan-
tile normalisation with no background correction to
those after using the neqc function in limma package,
which uses the various negative control probes on an
Illumina array to compensate for background signal
prior to quantile normalisation. As with the Affymetrix
arrays it is clear that performing additional background
correction has little effect on the relative variance struc-
tures but generally inflates the magnitudes of the esti-
mated variances.
A similar variance analysis was also performed, for
comparison, using the MAQC Illumina Human-6
Expression BeadChip (v1) dataset [11]. Expression levels
for 47,293 probes were subjected to the same detection-
filtering criteria as our Ref-8 and HT-12 chips and the
expressions of 21,896 surviving probes were quantile
normalised prior to variance analyses. The design of the
MAQC experiment only allowed for variance compo-
nents to be estimated for the inter-laboratory, inter-
chip, and inter-array levels. However, compared to the
Ref-8/HT-12 inter-experiment standard deviations, the
MAQC inter-laboratory standard deviations were much
smaller; less than half as much on average (Figure 3C).
This is likely to be a result of our use of different array-
versions and widely different dates on which the arrays
were processed (about 2 years). However it is note-
worthy that the majority of the variance in the MAQC
dataset was attributable to the intra-chip (inter-array)
level and this is the only dataset, for which variance ana-
lyses were performed, in which this phenomenon holds.
Variance analysis of the MAQC Affymetrix U133
Plus2.0 dataset (using 23,053 probes reported as ‘pre-
sent’ across at least 80% of the samples) revealed a more
familiar variance pattern, similar to that observed in our
experiments, in which the majority of the variation is
directly attributable to systematic differences between
the different laboratories performing the experiments
(Figure 3D). The estimated standard deviations at the
inter-laboratory level in these data were similar to those
observed at the inter-experiment level in the combined
Ref-8/HT-12 data, as were the distributions of the coef-
ficients of variation (standard deviation normalised by
mean expression; data not shown).
The Pearson-correlation heatmaps in Figure 4 demon-
strate that the majority of the variation between
Figure 4 Correlation heatmap of all replicate UHRR pairs.
Heatmap of Pearson correlations between replicate pairs of UHRR
samples highlights the inter-experiment, inter-run, and inter-chip
differences; particularly at the inter-experiment level. Red cells
correspond to ~80% correlation and white to 100% correlation.
Batches and sample numbers are consistent with the colouring and
labelling in Figures 1 and Additional File 2. A: detection filtered (DF);
B: DF & quantile normalised (QN); C: DF & QN &ComBat(by
experiment); D: DF & QN &ComBat(by run).
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Page 5 of 14replicate UHRR samples in our Ref-8/HT-12 data was
introduced as a result of the three separate experiments
(see methods and Additional File 2). However, some-
what surprisingly, the poorest correlations exist between
the two experiments involving the HT-12 chips (85.6%
between runs 6/7 and run 8) as opposed to (90.4%
between runs 1-5 and run 8). As previously observed,
standard normalisation techniques based on array-wide
intensity distributions, such as by quantiles or splines,
do little to improve probe-wise correlations between
replicate samples [15]. There is also an apparent band
of poorer correlation corresponding to a single HT-12
chip in run 7 (chip 22). For consistency with the control
samples hybridised to the Ref-8 chips, two replicates of
the original UHRR were retrieved from storage and
added to one chip in each run with the HT-12 chips in
experiment 2. However, only a marginal improvement
was observed in the correlation of these old UHRR sam-
ples compared to the freshly amplified and labelled
replicates (C1-18 vs. Cz1-Cz2 = 92.8% compared to C1-
18 vs. C19-22 = 91.2%). Although, again, the sample on
chip 22 was more poorly correlated with the UHRR
samples on the Ref-8 chips than that hybridised to chip
20, despite this chip appearing normal in all standard
QC checks and internal controls except, perhaps, for
slightly smaller bead-level standard errors compared to
the other chips (see methods).
All UHRR data were subjected to batch-correction
using ComBat and correction at two levels was assessed:
experiment-wise and run-wise correction. Following
ComBat correction by experiment, all pairwise correla-
tions increased to approximately the same level observed
in the quantile-normalised Ref-8 data obtained from the
first experiment (Figure 4C). However, we found pre-
viously that despite high correlation between UHRR
replicates the consistency between lists of statistically
significant differentially expressed probes from duplicate
sets of samples was poor without specific batch-correc-
tion [15]. Following ComBat correction by run, correla-
tions in these new UHRR samples approach those
observed in the original, ComBat batch-corrected UHRR
samples from the first experiment (Figure 4D).
Inter-batch calibrators: Comparing UHRR with pools of
tumour sample RNA
Two controls of pooled clinical breast-tumour RNA
were run on each of the four BeadChips in experiment
2 (samples P1 through P8 in Additional File 2). One
pool was created from a mix of all seven pre-treatment
samples run in this experiment and the second pool was
created using all seven post-treatment samples (see
methods). Results of pairwise Pearson-correlations
between these pooled samples identified a large
difference between chip 22 and the other three chips
used in this experiment (Figures 5A &5B), consistent
with that seen with the UHRR. No obvious differences
were observed in the correlations between the different
pools composed of either pre- or post-treatment RNA.
In general, the correlations appeared similar to those
observed between replicate UHRR samples illustrated in
Figure 4. As noted before, quantile normalisation does
little to remedy the poor correlation between chip 22
and the other chips, but this is remedied with ComBat
by treating the batches either as runs (Figure 5C) or,
slightly better, as separate chips (Figure 5D).
Compared to the UHRR samples in experiment 1 (Fig-
ure 3B), variance components estimated by nested-anova
between the pooled tumour samples (Figure 5) in
experiment 2 both show a large inter-chip/intra-batch
effect. The larger magnitude of variation supports the
increased inter-chip component in UHRR and it is clear
from both the correlations and the variance estimates of
both the UHRR and tumour pools that the variance in
the HT-12 data is driven by a particular chip (chip 22),
rather than between runs as was the case in the Ref-8
arrays.
Gene expression in this small group of samples was
rather varied, resulting in only 5 probes significantly dif-
ferentially expressed following treatment that also sur-
vived multiple-testing correction at q < 0.05; the same 5
probes appeared in every results list regardless of nor-
malisation or batch-correction. Despite the apparent low
level of biological variation between the pre- and post-
treatment samples and small number of significantly dif-
ferentially expressed genes, both the UHRR and the
pools accurately reproduced the fold-changes between
duplicate tumour samples across the two runs (Addi-
tional File 3). We calculated the differences in expres-
sion across the two batches for all duplicate pairs of
tumour samples and also between the UHRR/pool repli-
cates. The correlation between differences observed in
the tumour duplicates and either the UHRR or pool
controls increased with the magnitude of the difference,
although both the pre-and post-tumour pools were
found to be significantly better correlated compared to
UHRR (on average by 3.9% and 4.3%, using one-sample,
two-tail t-tests p < 5.9 * 10
-9 and p < 3.4 * 10
-9, respec-
tively). We also performed an exhaustive comparison of
the fold-change in expression due to the different runs
between the replicate pools of pre-treatment tumour
RNA and each of the fold-changes between duplicate
tumour samples (Additional File 4). In many cases there
was strong agreement between absolute expression dif-
ferences observed in the pool and the individual tumour
duplicates, however such agreement is not necessary in
order for the effect to be removed by ComBat,o r
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Page 6 of 14alternative correction methods, as the absolute magni-
tude of the effect is explicitly normalised during the cor-
rection procedure.
Properties of the probes with respect to batch variation
In order to assess if batch effects are uniform across all
genes, we investigated whether the properties of the
probes themselves were affected by different sources of
systematic error (see methods). Several descriptive sta-
tistics were selected to serve as measures of probe-
and mapping-specific properties that could conceivably
influence probe expression [25-28]. These included
compositional properties such as the guanine and cyto-
sine (GC) nucleotide content as well as mapping prop-
erties such as the position of the probe as a fraction of
the total length of the target gene, the number of
(known) transcripts consecutively probed, and the
average number of exons within the probed gene; with
the number of known transcripts and number of exons
acting as proxies for gene complexity and size,
respectively.
The distribution of GC-content over the Illumina HT-
12 probes (Figure 6A-top) clearly shows that they have
been designed with a bias such that the nucleotide dis-
tribution of the probes themselves favour a greater-
than-random fraction of GC-nucleotides. The GC-frac-
tion distribution of the 12,042 probes used in the analy-
sis of run-induced fold change is plotted as a Gaussian-
smoothed probability density in Figure 6B-top. Also
plotted is the distribution of the subset of these probes
found to be more than 2-fold up- or down-regulated
due to the batch effect in any of the 14 duplicate sample
pairs. These two distributions are very similar, suggest-
ing that a large number of these technical effects are
random fluctuations independent of GC-content. How-
ever the distribution of any probe found to be more
than 2-fold up- or down-regulated due to the batch
effect in at least 6 of the duplicate sample pairs was sig-
nificantly biased towards a lower GC-fraction (Figure
6B-top; c
2 p-value < 2.2 * 10
-16). Taking this further, we
correlated probe GC-fraction with error estimates from
the Ref-8/HT-12 UHRR replicates (Figure 3B), revealing
Figure 5 Correlation heatmap of all replicate pool pairs. RIGHT: Heatmap of Pearson correlations between replicate pairs of pooled-tumour
control samples highlights the inter-run and inter-chip variation; particularly at the inter-chip level. Red cells correspond to ~96% correlation and
white to 100% correlation. Batches and sample numbers are consistent with the colouring and labelling in Figures 1 and Additional File 2. A:
detection filtered (DF); B: DF & quantile normalised (QN); C: DF & QN &ComBat(by run); D: DF & QN &ComBat(by chip). LEFT: Variance estimates
at various levels in replicate pooled-controls hybridised to the HT-12 chips used in experiment 2. Highlights the effect of various normalisation
procedures on these variance estimates; as before, such procedures include detection-filtered (DF), quantile normalised (QN), ComBat corrected
by run (CB(run)), and ComBat corrected by BeadChip (CB(chip)).
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Figure 6 Batch effect and probe GC content. TOP: A, histogram of GC content over our Illumina HT-12 probes; B, gaussian-smoothed
probability density distribution (black, N = 48,803). Union of probes more than 2-fold up- or down-regulated due to the batch effect in any of
the 14 duplicate tumour-sample pairs from Additional File 4 (green line, N = 2,661). Union of probes more than 2-fold up- or down-regulated
due to the batch effect in more than 5 of the duplicate tumour pairs (red line, N = 207). BOTTOM: Plots of probe CG-fraction against standard
deviation estimated at the inter-experiment (A), inter-run (B), and inter-chip (C) levels in our combined Illumina Ref-8/HT-12 dataset. Red lines
denote the cutoff s used in chi-squared analysis at each level.
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Page 8 of 14highly significant enrichment for higher standard devia-
tions (SD) at lower GC-fractions (< 0.55) at the inter-
experiment (Figure 6A-bottom; c
2 pVal < 5.3 * 10
-8)
and inter-run (Figure 6B-bottom; c
2 pVal < 2.2 * 10
-16)
levels, but not at the inter-chip level (Figure 6C-bot-
tom). No significant association was observed between
low-signal probes and GC-content, however a small but
significant enrichment for highly-signal-low-GC probes
was found (Additional File 5).
We also compared probe GC content with our var-
iance estimates from the MAQC Illumina and Affyme-
trix datasets, both of which have a similar overall
distribution of probe-GC content, skewed in favour of
higher GC fraction (data not shown). A significant
enrichment for low-GC-high-SD probes was again
observed, both at the inter-laboratory level (c
2 pVal <
9.8 * 10
-8) and at the inter-chip level (c
2 pVal < 2.1 *
10
-4). As with the Ref-8/HT-12 data, there was no sig-
nificant enrichment at the lowest level between replicate
arrays. To determine whether this low-GC-high-SD
association was resolvable between biological as well as
technical replicates, we chose a subset of pre-and post-
treatment samples from our Illumina Ref-8 dataset
(these were pre-treatment biological replicates from run
3 and non-duplicated post-treatment biological repli-
cates from run 5 to avoid confounding due to inter-run
variation). Despite a slightly greater number of probes
with low-GC-high-SD in both the pre- and post-treat-
ment sample-sets, the trend was not significant (data
not shown).
The subset of pre-treatment biological replicates from
run 3 and non-duplicated post-treatment biological repli-
cates from run 5 were also used to test for any associa-
tion between probe-mapping properties and batch
effects. For each probe, the standard deviation between
the pre-treatment samples and, separately, the post-treat-
ment samples were assessed against probe position in the
target gene, number of concurrently probed transcripts,
and the number of exons in the target gene. The distribu-
tion of probe-location as a fraction of gene length among
the Ref-8 probes is shown in Additional File 6. After
adjusting for the strand of the target, there was no signifi-
cant association for increased standard deviations of
probes proximal to either the 3’ or 5’ end. To test
whether probe-mapping may correlate with variation
between replicate cRNA-syntheses, a similar analysis was
performed using the MAQC Illumina dataset. These
probes have a distribution similar to the Ref-8 arrays and
the analyses again revealed no significant enrichment for
estimated standard deviation due to probe position
(Additional File 7). It is therefore likely that such probe-
mapping effects can only be resolved when probes target
different regions of the transcript, rather than for probes
targeting the same region being affected by biological or
technical variability.
Discussion
Microarrays represent a powerful means of rapidly
assessing genome-wide expression patterns. Unfortu-
nately confounding technical variation and systematic
error in array technologies presents a major obstacle to
their adoption for clinical diagnostics in humans. These
factors are rarely documented, poorly understood, and
their implications for experimental and clinical utility of
microarrays frequently ignored [1,4]. Building on pre-
vious investigations of technical variation between repli-
cate RNA samples from breast tumour biopsies, this
extended study used both Illumina and Affymetrix
arrays to explore the reliability of reported expressions
across a variety of experiment designs. Re-analysis of
our MCF7 and MCF10A Affymetrix datasets demon-
strated that not compensating for one batch effect, such
a st h eu s eo fad i f f e r e n ts c a nner (Eg. if the information
was not available) would have a much smaller effect on
the numbers of genes identified as commonly differen-
tially expressed, than another batch effect (such as the
labelling method or if RNA was amplified).
Using a large combined dataset of conserved, reliably-
detected probes on Illumina Ref-8 and HT-12 BeadChips
(experiments 1 through 3) we found that the correlation
between replicate UHRR hybridisations were consistently
poorer than correlations previously reported using the
Ref-8 data alone [15]. Interestingly, we found that
labelled UHRR samples from the original experiment,
which were stored at -80°C for approximately two years,
hybridised to two arrays on the new HT-12 chips corre-
lated better with the original Ref-8 samples than did
freshly prepared UHRR replicates. This suggests that
even long periods of frozen storage and additional freeze-
thaw cycles introduce less noise into experimental mea-
surements than that inherent in creating a new prepara-
tion of labeled cRNA, even from the same RNA source.
As in our previous investigation [15], quantile normali-
sation did little to improve correlation between the
UHRR replicates across the Ref-8/HT-12 dataset. How-
ever specific batch-correction using ComBat [17] once
again significantly improved correlations and is a valuable
tool for removing systematic error introduced between
experiments and/or processing runs. The inter-chip var-
iation in the new HT-12 datasets was almost double what
it was in the Ref-8 dataset and due to this increase in
inter-chip variation and high-levels of inter-experiment
variation, the inter-run variation in the combined dataset
was largely obscured. However, as we have previously
seen, inter-experiment and inter-run variances were lar-
gely eliminated following ComBat corrections.
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were smaller in magnitude to the variances obtained
from our Ref-8 data, revealing a surprisingly high level of
reliability between the three laboratories that performed
these experiments. In contrast, the MAQC Affymetrix
dataset was found to be far more variable than their Illu-
mina data but similar to the magnitudes of variance
observed in both our combined Ref-8/HT-12 dataset and
our Affymetrix dataset. The reason for the low variation
in the MAQC Illumina data is unknown, especially since
their study design deliberately split the sample replicates
before cRNA synthesis; a much earlier stage in the sam-
ple-prep workflow than our replicates (which were split
after amplification and labelling). It is possible that the
small number of laboratories (three, in total) performing
the MAQC Illumina hybridisations produced highly con-
cordant data completely by chance, while the larger num-
ber of laboratories (six, in total) performing the
Affymetrix experiments provided a more realistic reflec-
tion of the technical variation in these data.
Pooled sample vs. UHRR as batch-effect calibrators
Several studies have found the use of replicate control
samples such as UHRR to be a useful standard in micro-
array experiments, suitable for monitoring expression
consistency within and across a variety of genome-wide
expression platforms [29-32]. However, such commercial
controls are deliberately generic and deficiencies have
been reported in terms of how well they represent speci-
fic cell types [33]. Clearly UHRR is not representative of
breast tumour RNA and therefore carries no guarantee
of expressing RNAs that may be variably expressed in
the specific subset of genes changed in breast tumour
tissue. Therefore, in terms of compensating for con-
founding technical variation, the very probes for which
the correction is most important are those that are most
neglected in the UHRR controls.
Unfortunately the relatively small degree of legitimate
biological differential expression between the pre-and
post-treatment tumour biopsies provided little opportu-
nity to assess the relative performance of UHRR and
pooled batch calibrators on the consistency of reported
differentially expressed probes. However, compared to
the UHRR, the pooled tumour RNA controls were
shown to more faithfully emulate the individual shift in
expression between tumour technical-duplicates as a
result of variation introduced between runs and between
chips. Had it been possible to identify more legitimately
differentially expressed probes between pre- and post-
treatment samples, the pooled RNA would almost cer-
tainly have made for a better batch-calibrator during
ComBat correction than the UHRR controls. If a similar
pooled calibrator was used in our previous study it
seems reasonable to speculate that the consistency
between the gene-lists reported as significantly differen-
tially expressed would have been noticeably higher than
the 74.1% achieved using UHRR calibrators.
Batch effects relative to probe position and composition
We took the opportunity to assess compositional prop-
erties of the probes as a potential explanation/surrogate
for the technical effects observed in the Ref-8/HT-12
data. A highly significant trend in favour of low-GC
content was identified in the core set of probes consis-
tently affected by inter-run and inter-chip variation
between sample duplicates. A similar, but less signifi-
cant, enrichment for low-GC-high-SD probes was also
observed in the MAQC Illumina dataset. This suggests
that the magnitude of error introduced due to low
probe GC-content is sufficiently great that it is resolva-
ble between the replicate cRNA preparations assessed in
the MAQC study. A similar observation regarding probe
GC-content and expression consistency was recently
reported in a comparison of RNA preservation proto-
cols, using matched samples, in terms of the effect on
results of downstream expression analyses [34]. A
further correlation of probe composition, specifically
with respect to GC-content, has been reported pre-
viously in a spike-in experiment using Illumina Bead-
Chips [35], in which it was found that probes with high-
GC content tended to have a higher than expected sig-
nal intensity, but probes with lower than average GC
content had inflated differential expression statistics. We
found no such association between low-expression and
GC-content, however we did observe a low-signal-low-
GC association; therefore the notion of inflated differen-
tial expression stats for low-GC probes is supported not
by probe intensity, but through greater variability in our
data. The low-GC effect is likely to be related to ther-
modynamic properties of hybridisation favouring high-
GC probes/targets, a supposition that is rational given
the deliberate high-GC bias in the design of the Illumina
probesets. Probes with low GC-content appear to be
inherently more vulnerable to systematic error but,
although highly statistically significant, the magnitude of
this variation in our data was small relative to that
between biological replicates. It is therefore somewhat
unlikely that such variation would pose a threat to the
accurate classification of samples and, even in an experi-
ment in which groups of biological replicates are poorly
distributed across chips and runs, is also unlikely to be
a serious confound to statistical tests for differential
expression.
The proximity, with respect to the target transcript, of
probes has been reported to strongly influence the cor-
relation of expression measurements between technolo-
gies [36]. The analyses performed here were designed to
assess whether such probe-transcript mapping
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however no such correlation was observed either
between biological or technical replicate samples. A
more thorough analysis of the MAQC datasets would
provide further insight into any relationship between
probe-location and expression between a variety of dif-
ferent platforms and sample-preparation procedures.
Conclusions
The key source of systematic error in any given micro-
array experiment is unpredictable, but can generally be
attributed to RNA extraction and, to some extent, label-
ling and amplification protocols. The results presented
here, including those derived from external data sources,
suggest that it is not recommended to analyse individual
test samples (e.g. to then try and classify), but instead to
run several at the same time to get a better estimate of
the experimental variation in order to be better
equipped to compensate for it.
Sound experimental design is of critical importance to
avoid confounding systematic variation. Randomisation
of samples over arrays on each BeadChip and careful
blocking of samples from each group of interest within
and across runs is necessary to protect against con-
founding systematic error. In situations where this is
not possible, detailed meta-data should be preserved for
e a c ha r r a yt h a ti n c l u d e s ,a tt h ev e r yl e a s t ,t h ed a t ea n d
time of each hybridisation and scan. In either case, diag-
nostic procedures such as PCA or SVA should be routi-
nely performed prior to downstream array analyses.
Methods
Samples and Arrays
RNA was extracted using the RNeasy Mini Kit, includ-
ing RNase-Free DNase treatment (Qiagen, Crawley, Uni-
ted Kingdom) from paired breast tumour tissue,
alternatively a Universal Human Reference RNA
(UHRR; Stratagene, Stockport, United Kingdom) was
used. RNA was amplified and biotinylated using Illu-
mina TotalPrep RNA Amplification Kit (Ambion) and
quantified on an Agilent 2100 Bioanalyser. 750 ng
cRNA per sample was hybridised to Illumina Human
R e f - 8v 2o rH u m a nH T - 1 2v 3e x p r e s s i o nB e a d C h i p s
(Illumina, Cambridge, United Kingdom) using the
Whole-Genome Expression Direct Hybridisation kit
(Illumina) and scanned with a BeadStation 500GX (Illu-
mina). Duplication of the clinical samples was per-
formed after labelling and labelled samples were stored
as per the manufacturer’s recommendations.
In addition to previously described samples [15,37],
four Illumina HT-12 (v3) BeadChips were used in a fol-
low-up experiment, described as ‘Experiment 2’ (Figures
1B and in Additional File 2). These chips were pro-
cessed in pairs over the course of two days (referred to
as runs). A single UHRR replicate, from a fresh prepara-
tion, was hybridised to each chip (’C19’-’C22’). Two
replicates of the original UHRR from the original study
were retrieved from storage at -80°C and one added to a
chip on each run (’Cz1’ and ‘Cz2’). Pools of pre-treat-
ment and post-treatment tumour RNA were created
from the clinical samples and each pool was then hybri-
dised to each chip. Three further Illumina Human HT-
12 (v3) BeadChips were processed over the course of a
single day, described as ‘experiment 3’ (see Additional
File 2). Additional UHRR samples were included in two
groups of replicates corresponding to different labelling
protocols; the first group of samples was obtained from
the same amplification and labelling (Ambion) as the
UHRR samples used in experiment 2 (’C23’-’C25’). The
second group of samples was labelled using the NuGen
amplification kit (NuGen) (’Cn1’-’Cn4’; Figure Addi-
tional File 2). The remaining samples on these Bead-
Chips were not analysed within this study.
Methods for generating the MCF7 and MCF10A tri-
plicate Affymetrix U133A data can be found in the ori-
ginal publication [14]. Methods for the MAQC Illumina
Human-6 Expression BeadChip (v1) and Affymetrix
U133 Plus2.0 array hybridisations are provided in [11].
All raw gene expression les and clinical annotation gen-
erated in this study are publicly available from the
caBIG supported Edinburgh Clinical Research Facility
Data Repository https://catissuesuite.ecmc.ed.ac.uk/caar-
ray/ and on request to the corresponding author.
Statistical Methods
Quality control analyses revealed no systematic or indi-
vidual problems with the Affymetrix or Illumina data at
the array level as assessed by the array-level distribu-
tions of signal intensities (Additional File 8). For the
Illumina Ref-8 and HT-12 arrays we also assessed the
noise distributions between replicate beads as large dif-
ferences in measurement precision might cause pro-
blems with the interpretation of results derived from the
combined datasets; however both the bead standard
errors and bead-representation on both Illumina chip-
types were very similar (Additional File 8).
Handling of Illumina data
All Illumina array scans were initially processed using
Illumina’s BeadStudio software using default parameters,
including removal of local background signal in the cap-
tured images but without background normalisation.
To perform reliable correlation and variance analyses
simultaneously on both Illumina chip-types, we identi-
fied and retained only the 15,757 probes with exactly
conserved sequences between Ref-8 and HT-12 that
also mapped uniquely to the genome. Probes were re-
mapped to the human genome (NCBI build 37) using
Bowtie [38] (v.0.12.7) allowing for no mismatched
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example the position of the probe within the host
gene, was provided by in-house software and the NCBI
RefSeq annotation database [39]. The 309 probes com-
mon to both the Ref-8 and HT-12 chips that aligned
t ot h eg e n o m eb u tf e l lw i t h in intergenic regions (or
those that, for whatever reason, were not covered by
the RefSeq annotation) were considered good and
retained, along with the 15,448 annotated intragenic
probes, for further analyses. All correlations, unless
otherwise stated, are based on Pearson’sp r o d u c t -
moment and are reported as percentages where 100%
is a perfect correlation.
These 15,757 uniquely mappable probes, represented
on both Ref-8 and HT-12 chips, were further filtered
(unless stated otherwise) using the detection confidence
reported by BeadStudio- determined for each probe
based on the expression of the internal control probes,
local background intensity, and the uniformity of the
reported intensity of the bead. The filtering was per-
formed prior to quantile normalisation such that probes
with a detection confidence less than or equal to 95% in
more than 20% of the samples were removed from
further analysis.
All Illumina data were detection-filtered and normal-
ised together (8,948 of the conserved probes passed the
detection-filter) before assessment by pairwise Pearson
correlation. Results of pairwise Spearman rank correla-
tions following separate filtering and normalisation of
the Ref-8/HT-12 chips were very similar (data not
shown). The globally filtered/normalised data were used
in all subsequent UHRR analyses for consistency with
our previous results and for a more reliable interpreta-
tion of nested variance analyses.
Handling of Affymetrix data
Affymetrix data were processed in R using functions con-
tained within the affy package. Expression values were
produced from probe in intensities using the expresso
function with, unless stated otherwise, RMA background
correction, quantile normalisation, and median-polish
summarisation over probesets. Following this preproces-
sing, probes were filtered such that those reported
‘absent’ in more than 20% of the samples were removed.
Variance estimation
We applied a linear additive model to the Affymetrix and
Illumina expression data on the log-scale to estimate the
specified variance contributions. These contributions are
assumed to be independent and randomly drawn from
log-normal distributions. As all factors meet in unique
combinations a nested, or hierarchical, variance model is
individually applied for each gene. Models of this kind
a r ef o r m a l l yd e f i n e di n[ 4 0 ]a n dh a v ep r e v i o u s l yb e e n
used in the context of gene-expression experiment design
[24,41]. Variance estimates in all analyses described
herein were performed using the REML procedure imple-
mented in the nlme package in R [42-44]. In all mixed
models the biological variables such as different cell-lines
in the Paterson dataset and the UHRR/UBRR dilutions in
the MAQC dataset were treated as fixed effects and all
downstream sample-processing levels treated as random
effects. The percentages reported in reference to the var-
iance structures, for example in Figure 3, were calculated
based on the mean standard deviation, of all linear mod-
els over all probes, attributed to each level.
Batch correction
The main difference between standard array normalisa-
tion and batch-correction is that the latter does not
make the assumption that all probes are affected equally
by batch-effects and, as such, performs individual adjust-
ments on each probe across all samples. The ComBat
approach, as discussed in detail in [17], is a somewhat
involved process, but can essentially be summarised in
three stages. First, using a method similar to autoscaling,
the data over all genes are standardised so that they all
have similar mean and variance. This step compensates
for the different expressions and variations of the var-
ious probes/genes that would otherwise bias the batch
effect estimates. Next the mean and variances of all
samples in each batch, over all probes/genes, are esti-
mated using a linear model and these parameters consti-
tute the first prior-distribution. Next, independently for
each gene, the sample mean and variance is estimated
for each batch and are used to estimate the parameters
of the additive and multiplicative noise distributions
using the method of moments; these constitute the sec-
ond prior-distributions. Finally, using the parameter esti-
mates for these two prior distributions along with Bayes
theorem, posterior distributions for each of the additive
and multiplicative noise distributions are calculated;
final values of these batch effect parameters are esti-
mated as the expected values of the posterior distribu-
tions. This empirical Bayes procedure allows
information from all genes to be used to estimate batch
effects for each gene, providing more stable estimates
than the standard sample mean and sample variance.
Differential expression
Gene expression changes were compared before and
after treatments and between responders and non-
responders using Bioconductor [45] algorithms imple-
mented in the statistical programming language, R
(v.2.12.1) [46]. Illumina probe pro le expression data
were normalised by quantiles and corrected for batch
processing effects using ComBat [17]. Genes differen-
tially expressed between paired pre- and post-treatment
samples were identified using limma (v.3.6.9) [47] and
SAM (v.1.28) [48]. For the analysis using limma, empiri-
cal Bayes variance shrinkage was employed and genes
were defined as being differentially expressed after
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mum, Benjamini-Hochberg adjusted, p-value of 0.01.
For the SAM analysis, the differentially expressed genes
were selected, following 100 permutations, at a maxi-
mum predicted false discovery rate of 5% and the same
minimum fold-change of ± 1.5.
R scripts and data archives can be downloaded from.
https://catissuesuite.ecmc.ed.ac.uk/caarray/
Additional material
Additional file 1: Supplementary material S1. Comparison of
estimated variance components in Affymetrix and Illumina data with and
without background correction as part of the array pre-processing.
Additional file 2: Supplementary material S2. Illustration of our
Illumina Ref-8 (experiment 1) and HT-12 (experiments 2 & 3) BeadChips,
processed in eight batches (also referred to as ‘runs’) corresponding to
the different days on which the samples were hybridised and scanned.
UHRR samples are labelled as C1-25. Replicate breast tumour clinical
samples are identified with a suffix of ‘a’ through ‘d’. The pre- and post-
treatment biopsy samples are identified by a triangle to the left and
right of the sample IDs, respectively.
Additional file 3: Supplementary material S3. Correlation of
expression change as a result of inter-run and inter-chip technical
variation between UHRR and pooled controls with tumour duplicates.
Tumour duplicates (individually plotted) are arranged on the x-axis to be
close to others processed on the same BeadChip. UHRR and both types
of pooled-control (comprised of pre- and post-treatment tumour RNA,
respectively) are correlated more strongly with individual tumour
duplicates in which one ‘half’ of the duplicate was processed on the
outlying chip 22. Pooled-controls also consistently score slightly higher
correlation than UHRR.
Additional file 4: Supplementary material S4. Scatter plots of fold-
changes between tumour duplicates and replicate pools. These plots
each show the magnitude of the change in expression between
technical replicates introduced by the runs and show how well
correlated such changes are between the Pool/tumour-duplicates. In the
figure, the pre-treatment tumour duplicate are coloured blue and post-
treatment are green; probes that are differentially regulated, up or down,
at least two-fold due to the different runs are highlighted in each plot
(red points). Note that most of the samples with a duplicate on chip 22
are subject to a greater magnitude of variation than samples with a
duplicate on chip 21.
Additional file 5: Supplementary material S5. Plot of GC-content vs.
(1/probe signal).
Additional file 6: Supplementary material S6. Distribution of MAQC
Illumina probes as a fraction of target gene length. Light blue points are
used for probes that mapped to the antisense DNA strand and dark blue
for the sense strand. Left plot represents the fraction of target gene
length in terms of 3’ and 5’ coordinates on each strand while the right
plot is ‘normalised’ for the anti-sense strand and plots the fraction in
terms of absolute position along the DNA molecule.
Additional file 7: Supplementary material S7. Probe position against
probe standard deviation: Plots of probe position against probe standard
deviation estimated at the inter-laboratory (A), inter-chip (B), and inter-
array (C) levels in the MAQC Illumina dataset. Light and dark blue points
again identify probes that mapped to the antisense and sense strands,
respectively.
Additional file 8: Supplementary material S8. Quality control metrics
over all of our Affymetrix and Illumina arrays including array-level
intensity distributions, Illumina bead-standard errors, and bead-
representation distributions between the two Illumina array-versions.
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